ASIC vs EQBK

ASIC's Piotroski F-Score of 4/9 indicates a borderline stable financial health, falling short of strong fundamentals. The absence of an Altman Z-Score raises concern about default risk, especially given the company's lack of disclosed debt and cash metrics. While the Graham Number ($21.31) and intrinsic value ($11.06) suggest undervaluation, the current price of $19.36 trades at a premium to intrinsic value, likely due to strong profitability and recent earnings surprises. The stock shows solid growth momentum in revenue (17.9% YoY) and consistent earnings beats (3/4 quarters), but earnings declined 9% YoY, creating a mixed signal. Analysts maintain a 'buy' recommendation with a $26.80 target, indicating optimism despite the valuation premium.

EQBK presents a stark contrast between fundamental health and market expectations. The deterministic health baseline is weak, highlighted by a Piotroski F-Score of 2/9, indicating significant deterioration in financial strength. While the stock trades at a substantial premium to its Graham Number ($32.33) and Intrinsic Value ($8.26), it is supported by a consistent track record of earnings beats and strong revenue growth (33% YoY). The massive discrepancy between the current P/E (38.42) and Forward P/E (8.61) suggests the market is pricing in a major earnings recovery that has yet to fully materialize in the ROE (3.44%).